Published in final edited form as:

J Cancer Res Clin Oncol. 2019 February ; 145(2): 337–344. doi:10.1007/s00432-018-2791-5.

Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial

Christina K. Cramer¹, Natalie Alphonse-Sullivan¹, Scott Isom³, Linda J. Metheny-Barlow¹, Tiffany L. Cummings⁴, Brandi R. Page⁸, Doris R. Brown¹, Arthur W. Blackstock Jr.¹, Ann M. Peiffer⁷, Roy E. Strowd^{4,5}, Stephen Rapp², Glenn J. Lesser⁵, Edward G. Shaw⁶, Michael D. Chan¹

¹Department of Radiation Oncology, Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157, USA

²Department of Psychiatry and Behavioral Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

³Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

⁴Department of Neurology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

⁵Department of Internal Medicine (Hematology & Oncology), Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

⁶Department of Internal Medicine (Gerontology and Geriatrics), Wake Forest School of Medicine, Winston-Salem, NC 27157, USA

⁷Department of Psychology, Mars Hill University, Mars Hill, NC 28754, USA

⁸Department of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA

Abstract

Introduction—Radiation-induced cognitive decline (RICD) is a late effect of radiotherapy (RT) occurring in 30–50% of irradiated brain tumor survivors. In preclinical models, pioglitazone prevents RICD but there are little safety data on its use in non-diabetic patients. We conducted a dose-escalation trial to determine the safety of pioglitazone taken during and after brain irradiation.

Christina K. Cramer ccramer@wakehealth.edu.

Compliance with ethical standards

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Data availability The clinical data used to support the findings of this study are included within the article. The [clinicaltrials.gov](https://clinicaltrials.gov/number/NCT01151670) number associated with this protocol is [NCT01151670](https://clinicaltrials.gov/number/NCT01151670).

Conflict of interest All authors declare that they have no conflicts of interest.

Methods—We enrolled patients > 18 years old with primary or metastatic brain tumors slated to receive at least 10 treatments of RT (3 Gy per fraction). We evaluated the safety of pioglitazone at 22.5 mg and 45 mg with a dose-escalation phase and dose-expansion phase. Pioglitazone was taken daily during RT and for 6 months after.

Results—18 patients with a mean age of 54 were enrolled between 2010 and 2014. 14 patients had metastatic brain tumors and were treated with whole brain RT. Four patients had primary brain tumors and received partial brain RT and concurrent chemotherapy. No DLTs were identified. In the dose-escalation phase, there were only three instances of grade 3 toxicity: one instance of neuropathy in a patient receiving 22.5 mg, one instance of fatigue in a patient receiving 22.5 mg and one instance of dizziness in a patient receiving 45 mg. The attribution in each of these cases was considered “possible.” In the dose-expansion phase, nine patients received 45 mg and there was only one grade 3 toxicity (fatigue) possibly attributable to pioglitazone.

Conclusion—Pioglitazone was well tolerated by brain tumor patients undergoing RT. 45 mg is a safe dose to use in future efficacy trials.

Keywords

Radiation-induced cognitive decline; Pioglitazone; Neuroprotective

Introduction

Radiotherapy (RT) is an integral component of treatment for primary and metastatic brain tumors. Radiation-induced cognitive decline (RICD) is a late effect of radiotherapy (RT) occurring in 30–50% of irradiated brain tumor survivors (Greene-Schloesser et al. 2012; Meyers et al. 2004). Factors that influence the likelihood and severity of radiation-induced cognitive dysfunction include the total dose, dose per fraction, the volume of brain irradiated, age at the time of radiotherapy, and prior or concurrent chemotherapy (Aoyama et al. 2006; Brown et al. 2003, 2016; Chang et al. 2009; Correa et al. 2009; Douw et al. 2009; Gondi et al. 2014; Klein et al. 2002; Schultheiss et al. 1995).

Microvascular damage, demyelination, direct damage to neurons and supportive brain parenchymal cells, stem cell depletion, and changes in the brain microenvironment have all been reported as components of radiation-induced brain injury (RIBI) which is the histopathologic correlate of RICD (Andrews et al. 2017; Gualtierotti et al. 2017; Hanbury et al. 2015; Monje et al. 2007; Price et al. 2001; Raber et al. 2004). Recent evidence indicates chronic oxidative stress and persistent neuro-inflammation after RT plays a key role in RIBI (Andrews et al. 2017; Monje et al. 2002; Robbins and Zhao 2004; Yoritsune et al. 2014). Inflammation-associated histologic findings include diffuse microglial activation, microglial aggregation at sites of necrosis, and mononuclear perivascular cuffing.

Identifying effective interventions to prevent or mitigate RICD has been challenging. For patients with established cognitive decline after RT, memantine, donepezil, methylphenidate, and *Ginkgo biloba* have all been tried as mitigating pharmacologic strategies with varying levels of success (Attia et al. 2012; Brown et al. 2013; Butler et al. 2007; Shaw et al. 2006). Pharmacologic radioprotection to prevent RICD is of great interest but has been less studied.

Ramipril, fenofibrate, tamoxifen, and indomethacin have all been studied preclinically (Greene-Schloesser et al. 2014; Jenrow et al. 2010; Liu et al. 2010) but translational trials in this realm have been sparse.

Pioglitazone is a member of the thiazolidinedione class of insulin-sensitizing drugs that has been used in the treatment of type II diabetes mellitus and also acts as a PPAR- γ agonist. There are emerging data that PPAR- γ agonist can be neuroprotective in stroke, Alzheimer's Disease and Parkinson's Disease (Breidert et al. 2002; Chang et al. 2015; Dehmer et al. 2004; Sundararajan et al. 2005; Zhao et al. 2005). Our institution was the first to show that pioglitazone reduces RICD in a rodent model (Zhao et al. 2007). In this study, rats who were fed pioglitazone daily during RT and after performed better on an object recognition task of short-term memory than irradiated rats who did not receive pioglitazone. The hypothesized mechanism of neuroprotection is via a transcriptional inhibition effect on the NF- κ B pathway which is a key mediator of the pro-inflammatory cascade triggered by RT. Chronic oxidative stress and inflammation are postulated to be the cause of normal tissue injury after RT leading to cognitive decline (Greene-Schloesser et al. 2012; Robbins and Zhao 2004). Studies also suggest that PPAR- γ agonists, including drugs in the thiazolidinedione class, can inhibit the growth of cell lines for prostate, ovarian, non-small cell lung, pancreatic, glioma and colon cancers (Grommes et al. 2004; Ban et al. 2010, 2011; Choudhary et al. 2010; Dong et al. 2009; Kim et al. 2011; Yokoyama et al. 2011). These data are encouraging, and there is great interest in doing a clinical trial in humans to see if the protective effect of pioglitazone seen in rodents is also seen in irradiated brain tumor patients.

Pioglitazone was FDA approved for the treatment of type II diabetes in 2012, and its toxicity profile is well documented. The most common toxicities of pioglitazone include peripheral edema, headache, dizziness, arthralgia, back pain, and infections. Hypoglycemia is also a reported toxicity but found more commonly when used in combination with another anti-hyperglycemic medication. The most serious toxicity is the increased risk of heart failure. A JAMA meta-analysis showed a 2.3% rate of serious heart failure in patients taking pioglitazone for diabetes (Lincoff et al. 2007). The rate was much lower in patients taking it for 6 months or less (only 4 patients out of more than 1,000 taking pioglitazone for 6 months or less developed heart failure). There have been reports of an increased incidence in bladder cancer for patients on pioglitazone, but the data are conflicting and inconclusive. Several recently published meta-analyses found either no definitive association between pioglitazone exposure and the development of bladder cancer or a very small association (Filipova et al. 2017; Li et al. 2017; Tang et al. 2018).

The population of brain tumor patients is unique when compared to any of the other populations in which the safety and efficacy of pioglitazone have been evaluated in the past. First, most brain tumor patients are often normoglycemic and using pioglitazone could potentially lead to hypoglycemia. Second, brain tumor patients often receive steroids which can cause hyperglycemia, weight gain, and extremity edema. While pioglitazone may beneficially counteract steroid-induced hyperglycemia, weight gain and edema are side effects of both steroids and pioglitazone. Concurrent use of steroids and pioglitazone might synergistically lead to unacceptable weight gain and edema. Additionally, brain tumor

patients are often taking antiepileptic medications and chemotherapy. The interaction of pioglitazone with these agents is not well understood. As a result, before designing a trial to determine the efficacy of pioglitazone as a cyto-protective agent to mitigate RICD, we needed to evaluate its safety in a population of brain tumor patients.

Materials and methods

Eligibility and exclusion criteria

Given that the safety of pioglitazone was not anticipated to differ by brain tumor tissue type, this study enrolled patients with primary or metastatic brain tumors. Patients > 18 years old who were anticipated to receive at least 10 treatments of RT (at 3 Gy per fraction or less) were eligible. Patients with a history of diabetes, NYHA class III or IV heart failure or symptomatic peripheral edema (grade 2 or greater) were not eligible for enrollment. Patients taking insulin or oral hypoglycemic agents for steroid-induced hyperglycemia were ineligible as were patients with a history of an allergic reaction to any thiazolidinedione. Patients could not be pregnant. Patients could not be taking any medication with a known interaction with pioglitazone or medications known to be a CYP3A4 inhibitor. Patients with a non-fasting blood glucose > 200 mg/dl, a fasting blood glucose > 125 mg/dl, AST or ALT > 2.5 the upper limit of normal, serum creatinine > 1.5, or hematocrit < 33% (men) or 30% (women) were not eligible for enrollment. Patients with uncontrolled intercurrent illness or unable to provide informed consent were also ineligible.

Trial design and drug therapy

This was phase I, single-institution, open-label, 3 + 3 dose-escalation trial with two dose levels (22.5 mg and 45 mg) and a planned dose-expansion phase. For each patient, their pioglitazone dose was assigned at enrollment and remained fixed. Pioglitazone was taken 5 days per week (Monday through Friday) during radiation and for 6 months after radiation. Patients were evaluated for adverse events including weight gain, edema, heart failure, or lab abnormalities attributable to pioglitazone weekly during RT and then at 1 month, 3 months and 6 months after the completion of RT. Patients were asked to keep a drug diary to monitor compliance. A dose-limiting toxicity (or DLT) was defined as (1) CTC 3.0 grade 3 weight gain, (2) grade 3 edema on the Peripheral Extremity Edema Scale, (3) CTC 3.0 grade 3 hypoglycemia and (4) New York Heart Association (NYHA) Classification of Heart Failure Grade 3 symptoms of heart failure. We selected these specific toxicities as DLTs since the safety of pioglitazone has been extensively evaluated in the past and our concern was potential magnification of weight gain, edema, hypoglycemia and heart failure in a brain tumor population. To estimate the toxicity rate within $\pm 26\%$ with 95% confidence, we anticipated needing 14 patients enrolled at the same dose level. We planned to enroll 18 patients to account for dropout. Pre-defined stopping rules specified that the study would be stopped if two patients experienced a DLT at the first dose level or if four patients total experienced a DLT. This study was approved by the Wake Forest Baptist Institutional Review Board (CCCWFU 97409). An IND exemption was procured from the FDA (IND 109658). Pioglitazone was purchased from Takeda Pharmaceuticals USA, Inc.

Results

18 patients were enrolled between August 2010 and 2014. 10 patients (55.6%) were female and 17 (94.4%) were white with a median age of 54 years (Table 1). The majority of patients ($n = 14$) received whole brain irradiation for brain metastases. Four patients received partial brain irradiation for primary brain tumors and all four of these patients received concurrent chemotherapy with either temozolomide or bevacizumab or a combination of the two. Three of these patients had recurrent gliomas and were receiving re-irradiation. Three of these four patients also received chemotherapy after radiation (one had a rapid decline in performance status after radiation and was admitted to hospice). Most patients ($n = 13$) had a BMI categorizing them as overweight or obese and most ($n = 16$) took steroids at some point during their treatment course.

No pre-specified DLTs were identified. In the dose-escalation phase, three patients received 22.5 mg and six patients received 45 mg. The adverse events according to dose level in the dose-escalation phase are reported in Table 2. There were only three instances of grade 3 toxicity: one instance of neuropathy in a patient receiving 22.5 mg, one instance of fatigue in a patient receiving 22.5 mg and one instance of dizziness in a patient receiving 45 mg. The attribution in each of these cases was considered “possible”. In the dose-expansion phase, nine patients received 45 mg and there was only one grade 3 toxicity (fatigue) which was also considered possibly attributable to pioglitazone (Table 3).

The average time that patients remained on pioglitazone treatment was 1.4 months. All but one patient discontinued pioglitazone because of a decline in their performance status related to disease progression. One patient electively discontinued pioglitazone after developing grade I lower extremity edema. Median survival was 5.5 months (Table 4; Fig. 1) and median follow-up time was 3.1 months.

Discussion

Pioglitazone at 22.5 mg and 45 mg is well tolerated by brain tumor patients undergoing RT. There were no pre-specified DLTs observed. Specifically, there were no instances of heart failure, hypoglycemia, extreme weight gain, or excessive peripheral edema which are recognized dose-limiting toxicities of this agent. Fatigue, dizziness, and neuropathy were observed. Pioglitazone appears to be safe in a population of brain tumor patients despite a pre-study concern for the potential of overlapping toxicities with steroids.

Several approaches to treating or preventing RICD are presently being explored in clinical trials including cytoprotective medications (Attia et al. 2014), symptom-relieving drugs (Brown et al. 2013; Rapp et al. 2015), and avoidance of critical targets within the brain that mediate cognitive performance post-radiotherapy (Gondi et al. 2014; Peiffer et al. 2013). Presently, a single-arm prospective study has been opened by the Wake Forest NCORP to assess the efficacy of ramipril in preventing RICD in glioblastoma patients. The concern for ramipril is the ability to penetrate the blood–brain barrier sufficiently at clinically tolerable doses. Pioglitazone has been shown to penetrate the blood–brain barrier, and, therefore, represents an intriguing cytoprotective option (Grommes et al. 2013). Moreover,

pioglitazone exerts anti-neoplastic effects on glioma cell lines (Grommes et al. 2004) and preclinical models (Ching et al. 2015; Papi et al. 2009).

The efficacy of pioglitazone in mitigating RICD in the preclinical setting has been shown in a rodent study published by Zhao et al. (2007). In this study, adult F344 rats were randomized to pioglitazone vs. no pioglitazone before, during and after whole brain irradiation for a total of 54 weeks of administration. Cognitive function, as measured by the novel object recognition test, was preserved in rats receiving pioglitazone during their whole brain irradiation. Fenofibrate, PPAR α agonist, has also been shown in preclinical studies to protect rats from RICD (Greene-Schloesser et al. 2014). In another mouse study, fenofibrate prevented a radiation-induced decrease in the number of newborn hippocampal neurons 2 months after whole brain irradiation (Ramanan et al. 2009). Moreover, the effects of fenofibrate were abolished in knockout mice, confirming the PPAR-mediated mechanism of preventing brain injury.

This study has several limitations. First, this was a heterogeneous sample that included primarily patients with brain metastases but also four glioma patients who received concurrent and adjuvant chemotherapies. Three of those four glioma patients were receiving their second course of radiation. This cohort was selected because the safety profile of pioglitazone was not anticipated to be different for primary or secondary gliomas; however, differences in radiation therapy dose and regimen are a limitation. Second, patient survival and follow-up were short which precluded any evaluation of chronic, late side effects from pioglitazone. The short survival is unsurprising since most enrolled patients had brain metastases for which they received whole brain RT. These limitations notwithstanding, this is the first trial to evaluate the safety of pioglitazone in brain tumor patients. There is preclinical evidence that pioglitazone may be able to mitigate RICD. Now that the short-term safety of pioglitazone has been established in the brain tumor population, we can move forward with evaluations of the efficacy of pioglitazone for this purpose. Presently, a phase II study is being planned with the goal of determining efficacy in mitigating RICD compared to a historical glioblastoma population and assessing the sample size necessary to power a potential randomized phase III trial.

Conclusion

Pioglitazone was well tolerated by brain tumor patients undergoing RT and no DLT was identified. 45 mg appears to be a safe dose to use in future efficacy trials.

Acknowledgements

The authors would like to acknowledge the late Dr. Mike E. Robbins, Ph.D., whose scientific work and advisement were integral to the development of this translational trial.

Funding This study was funded by grant number: P30 CA012197-40.

References

- Andrews RN et al. (2017) cerebrovascular remodeling and neuroinflammation is a late effect of radiation-induced brain injury in non-human. *Primates Radiat Res* 187:599–611. 10.1667/Rr14616.1 [PubMed: 28398880]

- Aoyama H et al. (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA* 295:2483–2491. 10.1001/jama.295.21.2483 [PubMed: 16757720]
- Attia A et al. (2012) Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. *J Neurooncol* 109:357–363. 10.1007/s11060-012-0901-9 [PubMed: 22700031]
- Attia A, Page BR, Lesser GJ, Chan M (2014) Treatment of radiation-induced cognitive decline. *Curr Treat Options Oncol* 15:539–550. 10.1007/s11864-014-0307-3 [PubMed: 25228143]
- Ban JO et al. (2010) Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. *Chem Biol Interact* 188:75–85. 10.1016/j.cbi.2010.06.001 [PubMed: 20540935]
- Ban JO et al. (2011) Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression. *Cancer Biol Ther* 12:288–296 [PubMed: 21613824]
- Breider T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. *J Neurochem* 82:615–624 [PubMed: 12153485]
- Brown PD et al. (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein minimal state examination. *J Clin Oncol* 21:2519–2524. 10.1200/JCO.2003.04.172 [PubMed: 12829670]
- Brown PD et al. (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind placebo-controlled trial. *Neuro Oncol* 15:1429–1437. 10.1093/neuonc/not114 [PubMed: 23956241]
- Brown PD et al. (2016) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. *JAMA* 316:401–409. 10.1001/jama.2016.9839 [PubMed: 27458945]
- Butler JM Jr et al. (2007) A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. *Int J Radiat Oncol Biol Phys* 69:1496–1501. 10.1016/j.ijrobp.2007.05.076 [PubMed: 17869448]
- Chang EL et al. (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol* 10:1037–1044. 10.1016/s1470-2045(09)70263-3 [PubMed: 19801201]
- Chang KL, Pee HN, Yang S, Ho PC (2015) Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease. *Sci Rep* 5:9000 10.1038/srep09000 [PubMed: 25760794]
- Ching J et al. (2015) The peroxisome proliferator activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells. *Oncotarget* 6:21301–21314. 10.18632/oncotarget.4019
- Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, Nemenoff RA (2010) Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. *Neoplasia* 12:224–234 [PubMed: 20234816]
- Correa DD, Rocco-Donovan M, DeAngelis LM, Dolgoff-Kaspar R, Iwamoto F, Yahalom J, Abrey LE (2009) Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. *J Neurooncol* 91:315–321. 10.1007/s11060-008-9716-0 [PubMed: 18974934]
- Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. *J Neurochem* 88:494–501 [PubMed: 14690537]
- Dong YW, Wang XP, Wu K (2009) Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. *World J Gastroenterol* 15:441–448 [PubMed: 19152448]
- Douw L et al. (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. *Lancet Neurol* 8:810–818. 10.1016/S1474-4422(09)70204-2 [PubMed: 19665931]

- Filipova E, Uzunova K, Kalinov K, Vekov T (2017) Pioglitazone and the risk of bladder cancer: a meta-analysis *Diabetes Ther* 8:705–726. 10.1007/s13300-017-0273-4 [PubMed: 28623552]
- Gondi V et al. (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. *J Clin Oncol* 32:3810–3816. 10.1200/JCO.2014.57.2909 [PubMed: 25349290]
- Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD (2012) Radiation-induced brain injury: a review. *Front Oncol* 2:73 10.3389/fonc.2012.00073 [PubMed: 22833841]
- Greene-Schloesser D et al. (2014) The peroxisomal proliferator-activated receptor (PPAR) alpha agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. *Radiat Res* 181:33–44. 10.1667/rr13202.1 [PubMed: 24397438]
- Grommes C, Landreth GE, Heneka MT (2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. *Lancet Oncol* 5:419–429. 10.1016/s1470-2045(04)01509-8 [PubMed: 15231248]
- Grommes C, Karlo JC, Capriarello A, Blankenship D, Dechant A, Landreth GE (2013) The PPARgamma agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. *Cancer Chemother Pharmacol* 71:929–936. 10.1007/s00280-013-2084-2 [PubMed: 23358645]
- Gualtierotti R et al. (2017) Modulation of neuroinflammation in the central nervous system: role of chemokines and sphingolipids. *Adv Therapy* 34:396–420. 10.1007/s12325-016-0474-7
- Hanbury DB et al. (2015) Pathology of fractionated whole-brain irradiation in rhesus monkeys (Macaca mulatto). *Radiat Res*. 10.1667/RR13898.1
- Jenrow KA, Brown SL, Liu J, Kolozsvary A, Lapanowski K, Kim JH (2010) Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus. *Radiat Oncol* 5:6 10.1186/1748-717x-5-6 [PubMed: 20122169]
- Kim S, Lee JJ, Heo DS (2011) PPARgamma ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. *Biochem Biophys Res Commun* 406:389–395. 10.1016/j.bbrc.2011.02.052 [PubMed: 21329655]
- Klein M et al. (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. *Lancet* 360:1361–1368 [PubMed: 12423981]
- Li Z, Sun M, Wang F, Shi J, Wang K (2017) Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis. *Int J Clin Pharmacol Ther* 55:210–219. 10.5414/cp202670 [PubMed: 28025963]
- Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *JAMA* 298:1180–1188. 10.1001/jama.298.10.1180 [PubMed: 17848652]
- Liu JL et al. (2010) Tamoxifen alleviates irradiation-induced brain injury by attenuating microglial inflammatory response in vitro and in vivo. *Brain Res* 1316:101–111. 10.1016/j.brainres.2009.12.055 [PubMed: 20044983]
- Meyers CA et al. (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. *J Clin Oncol* 22:157–165. 10.1200/JCO.2004.05.128 [PubMed: 14701778]
- Monje ML, Mizumatsu S, Fike JR, Palmer TD (2002) Irradiation induces neural precursor-cell dysfunction. *Nat Med* 8:955–962. 10.1038/nm749 [PubMed: 12161748]
- Monje ML, Vogel H, Masek M, Ligon KL, Fisher PG, Palmer TD (2007) Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. *Ann Neurol* 62:515–520. 10.1002/ana.21214 [PubMed: 17786983]
- Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, Heneka MT (2009) PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. *J Neurochem* 109:1779–1790. 10.1111/j.1471-4159.2009.06111.x [PubMed: 19457135]

- Peiffer AM et al. (2013) Neuroanatomical target theory as a predictive model for radiation-induced cognitive decline. *Neurology* 80:747–753. 10.1212/WNL.0b013e318283bb0a [PubMed: 23390169]
- Price RE, Langford LA, Jackson EF, Stephens LC, Tinkey PT, Ang KK (2001) Radiation-induced morphologic changes in the rhesus monkey (*Macaca mulatta*) brain. *J Med Primatol* 30:81–87 [PubMed: 11491408]
- Raber J et al. (2004) Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. *Radiat Res* 162:39–47 [PubMed: 15222778]
- Ramanan S, Kooshki M, Zhao W, Hsu FC, Riddle DR, Robbins ME (2009) The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. *Int J Radiat Oncol Biol Phys* 75:870–877. 10.1016/j.ijrobp.2009.06.059 [PubMed: 19801103]
- Rapp SR et al. (2015) Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. *J Clin Oncol* 33:1653–1659. 10.1200/JCO.2014.58.4508 [PubMed: 25897156]
- Robbins ME, Zhao W (2004) Chronic oxidative stress and radiation-induced late normal tissue injury: a review. *Int J Radiat Biol* 80:251–259. 10.1080/09553000410001692726 [PubMed: 15204702]
- Schultheiss TE, Kun LE, Ang KK, Stephens LC (1995) Radiation response of the central nervous system. *Int J Radiat Oncol Biol Phys* 31:1093–1112. 10.1016/0360-3016(94)00655-5 [PubMed: 7677836]
- Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, Rapp SR (2006) Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. *J Clin Oncol* 24:1415–1420. 10.1200/JCO.2005.03.3001 [PubMed: 16549835]
- Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. *Neuroscience* 130:685–696. 10.1016/j.neuroscience.2004.10.021 [PubMed: 15590152]
- Tang H, Shi W, Fu S, Wang T, Zhai S, Song Y, Han J (2018) Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. *Cancer Med* 7:1070–1080. 10.1002/cam4.1354 [PubMed: 29476615]
- Yokoyama Y, Xin B, Shigeto T, Mizunuma H (2011) Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. *J Cancer Res Clin Oncol* 137:1219–1228. 10.1007/s00432-011-0993-1 [PubMed: 21681689]
- Yoritsune E et al. (2014) Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis. *J Radiat Res* 55:803–811. 10.1093/jrr/rru017 [PubMed: 24676944]
- Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J (2005) The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. *Eur J Neurosci* 22:278–282. 10.1111/j.1460-9568.2005.04200.x [PubMed: 16029218]
- Zhao W, Payne V, Tommasi E, Diz DI, Hsu FC, Robbins ME (2007) Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. *Int J Radiat Oncol Biol Phys* 67:6–9. 10.1016/j.ijrobp.2006.09.036 [PubMed: 17189061]

Fig. 1.
Patient survival

Table 1

Patient characteristics

Age at registration [median (min, max)]	54 (31, 83)
Gender	
Female	10 (55.6%)
Male	8 (44.4%)
Race	
White	17 (94.4%)
Black	1 (5.6%)
BMI [median, (min, max)]	26.7 (18.7, 34.8)
Tumor type	
Primary	4
Metastatic	14
Radiation dose in Gy [median, (min, max)]	30 (30, 59.4)
Re-irradiation	
Yes	3
No	15
Concurrent chemotherapy during RT	
Yes	4
No	14
Taking steroids at any point during pioglitazone treatment	
Yes	16
No	2

Table 2

Adverse events attributable to pioglitazone in the nine patients in the doseescalation phase

Event, according to body system and grade	Number of patients	
	Level 1—22.5 mg (n = 3)	Level 2—45 mg (n = 6)
Dizziness, grade 3	—	1
Edema: limb, grade 1	1	2
Edema: limb, grade 2	—	1
Fatigue (asthenia, lethargy, malaise), grade 2	—	1
Fatigue (asthenia, lethargy, malaise), grade 4	1	—
Gastrointestinal—other (excessive thirst), grade 2	1	—
Glucose, serum-high (hyperglycemia), grade 2	1	2
Hair loss/alopecia (scalp or body), grade 1	—	2
Hyperpigmentation, grade 1	1	—
Infection—other (shingles), grade 2	1	—
Lymphopenia (1–5.1), grade 2	—	1
Mucositis/stomatitis (functional/symptomatic): oral cavity, grade 1	1	—
Neurology—other (lack of concentration), grade 1	1	—
Neuropathy: motor, grade 3	1	—
Pain: back, grade 1	1	—
Pain: bone, grade 2	1	—
Pain: muscle, grade 1	1	—
Rash: dermatitis associated with radiation; radiation, grade 1	1	—
Vomiting, grade 1	—	1

Attribution of “possible,” “probable,” or “related”

Table 3

Adverse events attributable to pioglitazone in the nine patients in the doseexpansion phase

Event, according to body system and grade	Number of patients (percent)				
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
Edema: head and neck	1 (11)	–	–	–	–
Edema: limb	2 (22)	–	–	–	–
Fatigue (asthenia, lethargy, malaise)	–	–	1 (11)	–	–
Glucose, serum-high (hyperglycemia)	1 (11)	–	–	–	–
Seizure	–	1 (11)	–	–	–

Attribution of „possible“, „probable“, or „related“

Table 4

Treatment and outcomes

Pioglitazone dose	
22.5 mg	3 (16.7%)
45 mg	15 (83.3%)
Duration of treatment from registration to last dose (months) [median, (min, max)]	1.4 (0.3, 8.6)
Duration of follow-up (months) [median, (min, max)]	3.1 (0.5, 15.2)
Median survival (months) (95% CI)	5.5 (1.7, 13.2)
Number of deaths	12